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Abstract. AChR-inducing activity (ARIA)/heregulin, 
a ligand for erbB receptor tyrosine kinases (RTKs), is 
likely to be one nerve-supplied signal that induces ex- 
pression of acetylcholine receptor (AChR) genes at the 
developing neuromuscular junction. Since some RTKs 
act through Ras and phosphatidylinositol 3-kinase 
(PI3K), we investigated the role of these pathways in 
ARIA signaling. Expression of activated Ras or Raf 
mimicked ARIA-induction of AChR e subunit genes in 
muscle cells; whereas dominant negative Ras or Raf 
blocked the effect of ARIA. ARIA rapidly activated 
erkl and erk2 and inhibition of both erks also abolished 
the effect of ARIA. ARIA stimulated association of 
PI3K with erbB3, expression of an activated PI3K led 
to ARIA-independent AChR e subunit expression, and 
inhibition of PI3K abolished the action of ARIA. Thus, 
synaptic induction of AChR genes requires activation 
of both Ras/MAPK and PI3K signal transduction path- 
ways. 
A  the neuromuscular junction forms, signals from the 
motor neuron  lead to  accumulation of nicotinic 
acetylcholine receptors  (AChR)  1 in the postsyn- 
aptic membrane (for review see  Hall and Sanes,  1993). 
Both  transcriptional  and  posttranslational  mechanisms 
contribute to this synaptic specialization. First, nerve-sup- 
plied factors induce subsynaptic nuclei to increase synthe- 
sis of AChRs (for review see Chu et al.,  1995b).  Second, 
nerve-evoked  electrical  activity results  in  repression  of 
AChR  synthesis  in  extrasynaptic  areas  (Laufer  and 
Changeux, 1989);  and  third, nerve-derived signals cause 
clustering of AChRs and other proteins on the muscle sur- 
face (for reviews see McMahan et al., 1992; Apel and Mer- 
lie,  1995; Bowe  and Fallon,  1995).  Recent progress  has 
been made in elucidating the molecular details of all three 
transynaptic pathways. Here, we explore the signal trans- 
duction mechanisms involved in motor neuron-dependent 
induction of gene expression. 
The hypothesis that a nerve-supplied factor selectively 
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affects the  transcriptional  activity of subsynaptic nuclei 
arose from studies showing synaptic enrichment of AChR 
subunit mRNAs (Merlie and Sanes, 1985). Subsequently, 
reporter  constructs linked to  AChR genomic fragments 
were shown to be selectively expressed by underlying syn- 
aptic  nuclei  in  transgenic  mice  (Klarsfeld  et  al.,  1987; 
Sanes et al.,  1991; Simon et al.,  1992; Gundersen et al., 
1993). These results supported a model in which the tran- 
scriptional potential of subsynaptic nuclei is controlled by 
a spatially restricted, nerve-supplied factor. 
The leading candidate for this neuronal factor is Acetyl- 
choline Receptor Inducing Activity (ARIA). Initially puri- 
fied from chicken brain on the basis of its ability to stimu- 
late  AChR  synthesis  in  aneural  myotubes  (Usdin  and 
Fischbach, 1986), ARIA was shown to induce expression 
of AChR subunit genes (Harris et al., 1988; Martinou et al., 
1991; Chu et al., 1995a; Jo et al., 1995). Sequence analysis 
of the ARIA gene (Falls et al., 1993) revealed that ARIA 
is encoded by the same gene that generates proteins ini- 
tially isolated as ligands of the neu proto-oncogene (hereg- 
ulin or NDF; Holmes et al., 1992; Wen et al., 1992) and as 
glial growth factor (Marchionni et al., 1993). Numerous al- 
ternatively spliced messages from the ARIA gene  have 
been detected (for reviews see Ben-Baruch and Yarden, 
1994; Corfas et al., 1995). In situ hybridization studies indi- 
cate that before innervation, ARIA is present in embry- 
onic motor neurons lying in the ventral horn of the spinal 
cord  (Falls et al.,  1993; Marchionni et  al.,  1993).  In the 
adult, immunoreactive ARIA protein can be detected at 
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rock et al., 1995). Functionally, ARIA has been shown to 
induce specific expression of the AChR genes in tissue cul- 
ture models (Martinou et al., 1991; Chu et al., 1995a; Jo et al., 
1995). 
ARIA/heregulin/GGF are  ligands  for EGF  receptor- 
related (erbB)  tyrosine kinases neu/erbB2/HER2 (Barg- 
mann et al., 1986), erbB3/HER3 (Kraus et al., 1989), and 
erbB4/HER4(Plowman et al., 1990; 1993). All erbB recep- 
tor tyrosine kinases (RTKs) have been shown to interact 
with heregulin (HRG) in various cell types (for review see 
Carraway  and  Cantley,  1994; Carraway  and  Burden, 
1995). In muscle, ARIA, erbB2, and erbB3 are colocalized 
and enriched at the neuromuscular end-plate (Altiok et al., 
1995; Jo et al., 1995; Moscoso et al., 1995; Zhu et al., 1995) 
and ARIA has been shown to cause phosphorylation of 
erbB  receptor  complexes in  muscle cells  (Altiok et  al., 
1995; Jo et al., 1995). Thus, erbB kinases are likely to be 
physiologically relevant ARIA receptors at the neuromus- 
cular synapse. 
The actions of a number of RTKs, including the recep- 
tors for EGF, PDGF, and insulin have been shown to in- 
volve recruitment of SH2-domain-containing proteins (for 
review see  Schlessinger,  1994)  which activate the  GDP/ 
GTP-binding protein p21Ras, implicated as a key interme- 
diate relaying signals between RTKs and a number of ef- 
fectors (McCormick, 1994; Burgering and Bos, 1995).  A 
major downstream target of Ras is  the serine/threonine 
protein  kinase  Raf-1  (Daum  et  al.,  1994; McCormick, 
1994),  which in turn controls the mitogen-activated pro- 
tein kinase (MAPK) cascade that controls gene expression 
and protein synthesis by phosphorylation of transcription 
factors and other kinases (for review see Marshall, 1994; 
Robbins et al.,  1994). Growth factors and neurotransmit- 
ters activate the Ras cascade (Ras/Raf/MEK/MAPK) in a 
number of cell types (Blenis, 1993). 
It  has  been  predicted  that  tyrosine-phosphorylated 
erbB2  and erbB3  may interact with  a  number of SH2- 
domain-containing proteins including phospholipase C -% 
guanine  nucleotide-activating  protein  (GAP),  the  Ras 
adapter Grb2, SHC, the p85 subunit of PI3K, and others 
(Carraway  and  Cantley,  1994).  Heregulin  activates  the 
MAPK cascade in proliferating mammary epithelial cells 
overexpressing erbB2 (Marte et al., 1995). Moreover, acti- 
vation of erbB2 by point mutation (Ben-Levy et al., 1994) 
or by monoclonal antibodies directed against the extracel- 
lular domain of erbB2 (Marte et al.,  1995), increases the 
activities of the MAP kinases, erkl  and erk2, in various 
cell lines. Thus, based on the results obtained in nonmus- 
cle cells, transduction of the ARIA/HRG signal between 
muscle  and  nerve  may  involve  activation  of  the  Ras/ 
MAPK pathway. 
More recently, experimental evidence has linked activa- 
tion  of  erbB3  to  that  of  phosphatidylinositol 3-kinase 
(PI3K), a lipid kinase previously shown to mediate the mi- 
togenic signal of the PDGF receptor (Cantley et al., 1991; 
Valius  and  Kazlauskas,  1993).  PI3K  products  (PI(3,4)P 
and PI(3,4,5)P) have been implicated in regulation of mi- 
togenesis, membrane ruffling, glucose uptake, and recep- 
tor sorting and downregulation in response to growth fac- 
tors (for review see Kapeller and Cantley, 1994). ErbB3 is 
the only erbB kinase which contains six putative tyrosine 
phosphorylation sites (YXXM) in its cytoplasmic domain 
for specific association with PI3K.  Association of PI3K 
with erbB3, but not with EGFR or erbB2, has been ob- 
served in EGF-treated human cancer cell lines (Soltoff et al., 
1994).  Heregulin-induced  tyrosine  phosphorylation  and 
association of erb2  and  erbB3  with PI3K has  been  re- 
ported in PC-12 cells (Gamett et al., 1995), in mouse fibro- 
blasts transfected with a chimeric EGFR/erbB3 receptor 
(Fedi et al., 1994), and in fibroblasts overexpressing erbB2 
and transfected with erbB3 (Carraway et al., 1995). Thus, 
recruitment of PI3K by an  activated erbB3 may be  an- 
other mechanism by which ARIA conveys its synaptic sig- 
nal to alter transcription of specific genes in muscle. 
In this study, we sought to determine whether the Ras/ 
MAPK or PI3K pathways were involved in mediating the 
effects of ARIA on induction of the AChR subunit genes. 
For this purpose, we studied expression of lacZ and CAT 
reporter constructs containing the AChR •  subunit pro- 
moter in an ARIA-responsive muscle cell line, Sol 8. Dif- 
ferentiated Sol 8 myotubes increase AChR •  subunit ex- 
pression  in  response  to  ARIA  (Chu  et  al.,  1995a)  and 
express both erbB2 and erbB3 receptors (Moscoso et al., 
1995); and therefore they represent a  suitable model for 
investigation  of  the  signaling  pathways  activated  by 
ARIA. Results obtained with pharmacological inhibitors 
and constructs encoding dominant negative or activated 
elements of the Ras and PI3K signaling pathways indicate 
that ARIA-dependent induction of AChR ~ subunit gene 
requires  both  pathways. These  results  provide  the  first 
demonstration that these signaling proteins can regulate 
expression  of synapse-specific genes  in  response  to  the 
ARIA synaptic signal. 
Materials and Methods 
Reagents 
Recombinant heregulin (HRGI31 residues 177-244)  was provided by M.X. 
Sliwkowski of Genentech (San Francisco, CA). PD 098059,  the selective 
MEK inhibitor was provided by A. Saltiel of Parke-Davis/Warner-Lam- 
bert Pharmaceuticals (Ann Arbor, MI). The PI3K inhibitor, LY294002, 
was purchased from BiomolResearch (Plymouth Mtg., PA). Anti-phos- 
photyrosine antibody (4G10) was purchased from Upstate Biotechnology, 
Inc. (Lake Placid, NY) and used according to the manufacturer's specifi- 
cations. Radiolabeled PIP marker for PI3K chromatography was obtained 
from H. Hope and prepared as described (Hope and Pike, 1994).  Unless 
otherwise specified, all other chemicals were purchased from Sigma Phar- 
maceuticals (St. Louis, MO). 
Tissue Culture and Transfections 
Sol 8 cells, a fusion-competent mouse muscle cell line (Mulle et al., 1988) 
were maintained and transfected as described in Chu et al. (1995a). In ex- 
periments where no signaling construct was used, the pSKII+ plasmid was 
cotransfected as filler DNA. In experiments where CAT constructs were 
used, RSV-IacZ was cotransfected to adjust for variations in transfection 
efficiency (Chu et al., 1995a).  Cells were transfected on day 1, switched to 
differentiation media (2%  horse serum) on day 2, and stimulated with 
ARIA/recombinant HRG (3 nM) on day 3 for the times specified in each 
experiment. In experiments involving inhibition of MEK, cells were pre- 
treated for 30 min with 50 ~M PD 098059 (dissolved in DMSO to stock 
concentration of 50 mM) or DMSO vehicle before the addition of ARIA. 
In experiments involving PI3K inhibition, cells were pretreated for 30 min 
with 20 ~xM LY294002 (dissolved in DMSO to a stock concentration of 
8 mM) or DMSO vehicle before the addition of ARIA. Transfected cells 
were harvested for 13-galactosidase  histochemistry or CAT assays on day 5. 
Transfected cells were harvested on day 4 in experiments involving use of 
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sured in untransfected cells harvested on day 6 after plating. 
Plasmid Constructs 
Constructs  referred  to  as  e-CAT  and  ~nlacZ  are  e150CAT  and 
~3500nlacZ, respectively, and have been described previously (Sanes et al., 
1991;  Sunyer and Merlie, 1993).  The e150CAT contains the 150-bp pro- 
moter sequence fused to the CAT gene. The ¢3500nlacZ construct con- 
tains the entire 3.5-kb of the AChR •  subunit gene promoter fused to 
nlacZ. The construct ActinCAT contains a  245-bp EcoRI-HindIII frag- 
ment of promoter sequence from the human cardiac a-actin gene (Miwa 
and Kedes, 1987)  fused to the CAT gene. The construct RSV-lacZ de- 
scribed  previously (Pronin  and  Gautam,  1992)  was  cotransfected with 
CAT constructs to normalize for transfection efficiency in Sol 8 cells. 
All signaling constructs were subdoned into a pSK-based parent vector 
driven by the 850-bp fragment of the AChR ct-suhunit promoter to direct 
myotube-specific expression (Klarsfeld  et  al.,  1987;  Prody  and  Merlie, 
1991)  of the signaling constructs and avoid expression in myoblasts that 
might interfere with proliferation  and subsequent myotube fusion. The 
parent vector also contains the AChR a-subunit polyadenylation signal 
downstream of the inserted cDNAs for efficient transcript processing in 
muscle cell lines. The activated Ras construct, referred to as AcRas, con- 
tains the HaRas (RasVa112) eDNA (done HB-11) and was obtained from 
Amer. Type Culture Collection (Rockville, MD). The dominant-negative 
Ras construct, referred to  as DnRas contains the eDNA originally de- 
scribed as N17Ras (Feig and Cooper, 1988).  The dominant-negative Raf 
(DnRaf), the negative control for dominant-negative Raf (ADnRaf), and 
the activated Raf (AcRaf) constructs contain the cDNAs described previ- 
ously as RafC4, RafC4pm17, and RafBXB, respectively (Bruder  et al., 
1992). The activated PI3K (AcPI3K) and negative control PI3K (AAcPI3K) 
constructs contain the cDNAs originally described as p110" and p110*Akin, 
respectively (Hu et al., 1995)  and were obtained from Anke Klippel at 
Chiron Corporation (Emeryville, CA). 
~-Galactosidase Assay 
Transfected cells were rinsed twice with PBS and fixed in 2% paraformal- 
debyde, 0.2% glutaraldehyde in PBS for 5 min. Cells were stained using 
X-GAL  histochemistry procedures  described  previously  (Sanes  et  al., 
1986).  Enzymatic quantitation of [3-galactosidase activity was performed 
using ONPG  as the substrate with minor modifications of the protocol 
previously described (Chu et al., 1995a).  Cells were rinsed twice with PBS 
and harvested in lx  Reporter Lysis Buffer (Promega, Madison, WI) for 
15 min and subjected to centrifugation at 12,000  rpm for 5 min. Cell ly- 
sates were incubated in 0.1 M sodium phosphate (pH 7.0) containing 0.64 
pxg/ml ONPG, 10 mM MgC12, and 450 mM [3-mercaptoethanol until reac- 
tion was visibly yellow. Absorbance was measured at OD420. 
CA  T Assays 
CAT assays were performed according to the method of Gorman (1985) 
as  modified by  Chu et  al.  (1995a).  13-Galactosidase activity  (from  the 
cotransfected  RSV-IacZ  plasmid)  was  used  to  adjust for  variations  in 
transfection efficiency. Extracts were assayed for CAT activity per 13-galac- 
tosidase OD  unit which was then expressed as Relative  CAT activity. 
CAT assay reaction buffer consisted of 0.25 M Tris-HC1 (pH 8.0) with 0.2 
ixg/ml bovine serum albumin as carrier.  Samples were subjected to thin 
layer chromatography in buffer containing 95% chloroform/5% methanol 
(vol/vol)  and  reaction  products were  quantified using phosphorimager 
analyses (Molecular Dynamics, Sunnyvale, CA). 
Immune Complex Kinase Assays 
Cells were harvested for MAP kinasc activity assays as described by Se- 
vetson et al. (1993). Antibodies against erkl (X-837) and erk2 were kindly 
provided by Melanie Cobb and John Lawrence, respectively, and used in 
immunoprecipitations as described (Sevetson et al., 1993).  The immuno- 
precipitated  MAP kinase activity and unprecipitated  material were  as- 
sayed using [~,-32p]ATP and myelin basic protein (MBP) as substrates as 
described by Boulton and Cobb (1991) with modifications of Sevetson et 
al. (1993). 
In-gel MAPK Assays 
Cell lysates were prepared as described above for immune complex kinase 
assays. Myelin basic protein was used as a substrate with 25 ~g total pro- 
tein of each cell lysate as described (Samuels et al., 1993).  Radioactivity 
was visualized by phosphorimager analyses. 
PI3K Activity Assays 
Cells were lysed in PI3K lysis buffer as described by Newberry and Pike 
(1995). Approximately 400 p~g of lysate protein and 45 pd of anti-phospho- 
tyrosine (4G10)  antibody (Upstate Biotechnology, Inc.), anti-erbB2 (sc- 
284,  Santa  Cruz  Biotechnology, Santa  Cruz,  CA),  anti-erbB3  (sc-285, 
Santa Cruz) antibody, or nonimmune rabbit IgG were added to the sam- 
ples and incubated overnight at 4°C while rotating end over end. Immune 
complexes were isolated using 25 p,l of Immuno-Precipitin (BRL) beads 
and washed twice with PBS +  1% Triton X-100, twice with 0.5 mM LiCI, 
10 mM Tris, pH 7.5, and twice with 10 mM Tris, pH 7.5, 100 mM NaCI, 1 
mM EDTA. PI3K activity was measured essentially as described by Au- 
ger et al. (1990). PI 3-P was identified based on its migration relative to 
that of a radiolabeled PI marker prepared as described by Hope and Pike 
(1994). Radioactivity was visualized by phosphorimager scanning. 
Western Blot Analyses 
In experiments where confirmation of quantitative immunoprecipitation 
of erbB  tyrosine kinases with anti-erbB2 or anti-erbB3 antibodies was 
performed, aliquots of immune complexes obtained as described for PI3K 
activity assays were solubilized in 5x Laemmli SDS sample buffer. Sam- 
ples were boiled for 5 min and after centrifugation, a  30-p.g protein was 
loaded  onto  10%  SDS-polyacrylamide gels. After electrophoresis, pro- 
teins were transferred onto PVDF (Immobilon, Millipore, Bedford, MA) 
membranes and immunoblotted with anti-erbB2 or anti-erbB3 antibody 
(Santa Cruz Biotechnology, sc-284 and sc-285, respectively, each diluted 1: 
1,000)  or nonimmune IgG. After incubation with a goat anti-rabbit alka- 
line phosphatase-conjugated secondary antibody diluted  1:1,000  (Boeh- 
ringer Mannheim, Indianapolis, IN), blots were subject to the enhanced 
chemiluminescent (ECL) detection method (Dupont, Boston, MA). 
In  experiments where  the ARIA-dependent  activation  of erkl  and 
erk2 was measured, samples were harvested directly in 2x Laemmli SDS 
sample buffer, diluted appropriately,  boiled, sonicated, and centrifuged 
before loading onto 10% SDS-polyacrylamide gels. After electrophoresis 
and  electroblotting  onto  PVDF  membranes, immunoblot analysis was 
performed using an anti-phosphotyrosine MAP kinase antibody diluted 1: 
1,000  (New England Biolabs, Beverly, MA) according to manufacturer's 
specifications. 
Results 
Requirement  for Ras and Raf in ARIA-induced A ChR 
• Subunit Gene Expression 
Since previous evidence suggests that ARIA receptors are 
erbB kinases, and erbB RTKs are known to activate the 
Ras pathway, experiments were performed to determine 
whether specific induction of the AChR ~ subunit gene by 
ARIA requires Ras. Sol 8 cells transfected with ~nlacZ, a 
construct bearing the full-length promoter of the AChR 
gene fused to the reporter lacZ, exhibited little expression 
of the AChR ~ subunit reporter construct (Fig. i a). How- 
ever, when  transfected  cells  were  treated  with  ARIA, 
~nlacZ expression was observed in nuclei within many myo- 
tubes (Fig. 1 a'). To investigate the role of Ras in ARIA- 
dependent  gene expression, we placed various  Ras con- 
structs under the control of a myotube-specific promoter 
to achieve postmitotic expression of these signaling con- 
structs and minimize their interference with early myogen- 
esis (see Materials and Methods). First, we asked if coex- 
pression  of an  activated  ras  (AcRas)  had  an  effect  on 
enlacZ expression. AcRas is a RasVa112 mutant trapped in 
the  active  form  (GTP-bound)  due  to  its  insensitivity  to 
GTPase-activating proteins (Ellis et al., 1981). Cotransfec- 
tion of AcRas with ~nlacZ resulted in reporter gene activa- 
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reporter by ARIA in Sol 8 myo- 
tubes and effects of various Ras 
and  Raf constructs.  Constructs 
were  transiently  transfected 
into Sol 8 myotubes. Cells trans- 
fected with  enlacZ plus  (a)  no 
signaling  construct  but pSKII+ 
plasmid  used as filler DNA; (b) 
AcRas;  (c)  DnRas;  (d)  AcRaf; 
(e) DnRaf; and (f) ADnRaf.  At 
24 h after the induction of differ- 
entiation,  ARIA (3  nM  HRG) 
was added  to the  wells (a'-f'). 
Cells  were  stained  for  [3-galac- 
tosidase  2 d later.  Each plasmid 
set  was  transfected  in  dupli- 
cate; the data shown are repre- 
sentative for results obtained in 
four to  five independent  trans- 
fections. Bar, 300 p,m. 
tion in the absence or presence of ARIA (Fig. 1, b and b'). 
Thus, activated Ras can bypass the requirement for ARIA. 
Next, we determined whether Ras was necessary for the 
response to ARIA. Sol 8  cells were transfected with en- 
lacZ and a dominant negative inhibitory (RasN17) mutant 
of Ras (DnRas).  This mutant forms an inactive complex 
with Ras guanine nucleotide dissociation stimulators (i.e., 
Sos) and prevents activation of endogenous Ras proteins 
(Feig  and  Cooper,  1988).  DnRas  blocked  the  ARIA- 
induced AChR e subunit expression (Fig. 1, c and c'), again 
suggesting that functional Ras is required for ARIA sig- 
naling. 
To investigate further the role of Ras and provide quan- 
titation of the effects described above, we repeated the ex- 
periments using a  construct  bearing a  fragment of the e 
promoter fused to the bacterial reporter chloramphenicol 
acetyltransferase (e-CAT). In cells transfected with e-CAT 
alone, a 5-6-fold induction by ARIA of e-driven CAT ex- 
pression was observed (Fig. 2 A), consistent with previous 
findings (Chu et al., 1995a). Cotransfection of AcRas with 
e-CAT caused a 6-7-fold increase in e-driven CAT expres- 
sion that was not increased further by ARIA. In contrast, 
cotransfection of DnRas with e-CAT did not significantly 
change basal  CAT expression,  but  DnRas  abolished  the 
ARIA-induced e-CAT expression (Fig. 2 A). Transfection 
cells with  a  control  construct  bearing  a  fragment of the 
cardiac et-actin promoter fused to  CAT  (ActinCAT)  re- 
suited in a marked increase in CAT activity which was not 
changed by ARIA or either Ras construct. These results 
indicate that direct activation of Ras is sufficient to mimic 
ARIA as well as necessary for transduction of the ARIA 
signal. 
Since Ras signaling by RTKs has been shown to be di- 
rectly  linked  to  activation  of  Raf,  we  next  investigated 
whether Raf was involved in mediating the ARIA  signal 
to increase AChR e subunit expression. Cotransfection ex- 
periments were  performed with  activated and  dominant 
negative  Raf constructs  using  methods  described  above 
for Ras. Activated Raf (AcRaf) has constitutively active 
kinase activity because it lacks a  cysteine-rich regulatory 
domain  (Bruder  et  al.,  1992).  Cotransfection  of enlacZ 
with activated Raf (AcRaf) resulted in significant activa- 
tion of enlacZ expression in nuclei within many myotubes 
in the absence of ARIA (Fig. 1 d'). In contrast, cotransfec- 
tion of a dominant negative Raf (DnRaf) which lacks the 
Raf kinase  domain abolished  the  ARIA-induced  enlacZ 
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Figure 2.  Induction of e-CAT expression by ARIA in Sol 8 tran- 
sient transfection  and effect of Ras and Raf constructs.  (A) Ras 
or (B) Raf constructs  were transiently  cotransfected with e-CAT 
into Sol 8 myotubes, At 24 h after the induction  of differentia- 
tion, ARIA (3 nM HRG) was added to the wells. Cells were har- 
vested for analysis 2 d later. A cotransfected plasmid encoding 
[3-galactosidase activity was used  to normalize for variations  in 
transfection efficiency among constructs.  ActinCAT was used to 
demonstrate the specificity of ARIA induction  of e-CAT expres- 
sion and showed no sensitivity to signaling constructs. Each plas- 
mid set was transfected in duplicate; the data shown represent av- 
erage values  from five to six independent  transfections,  Error 
bars indicate SEM. See text for description  of plasmids. 
expression (Fig. 1, e and e'), whereas cotransfection with 
its negative control  (ADnRaf)  did  not affect the  ARIA- 
specific induction  of cnlacZ expression  (Fig.  1, f  and f) 
and gave the same results as cnlacZ alone (Fig. 1, a and a'). 
Quantitation of these effects using t-CAT confirmed that 
expression of activated Raf results in ARIA-independent 
t-CAT expression (Fig. 2 B) and that expression of domi- 
nant  negative  Raf (DnRaf)  abolishes  the  ARIA-depen- 
dent increase. Cotransfection of Raf constructs had no ef- 
fect on ActinCAT expression or its ARIA-responsiveness. 
Thus, activation of a Raf-mediated pathway can substitute 
for ARIA-receptor activation and is necessary for ARIA- 
induced AChR c subunit expression. 
Requirement for MAPK in ARIA-induced A ChR e 
Subunit Gene Expression 
Although Raf has been demonstrated to activate multiple 
substrates, its most common target is the MAPK kinase or 
MEK. Therefore, we examined the role of MEK and its 
known downstream effectors, the MAP kinases, erkl and 
erk2, in mediating the ARIA signal by use of a  selective 
inhibitor  of MEK  activation,  PD  098059.  Incubation  of 
cells with PD 098059 blocks the activation of MEK and the 
downstream MAPKs, erkl and erk2 (Dudley et al., 1995; 
Pang et al., 1995). Moreover, PD 098059 does not inhibit 
the MAPK homologues JNK (jun kinase) and P38, PI3K, 
other  protein  serine/threonine  kinases  including  Raf, 
cAMP-dependent protein kinase and protein kinase C, or 
the  tyrosine kinase activities of v-src, EGFR,  insulin  re- 
ceptor,  or  PDGFR  (Dudley  et  al.,  1995).  More  impor- 
tantly, in Sol 8 cells, PD 098059 did not inhibit PI3K activ- 
ity (see below). Thus, we reasoned that inhibitory effects 
of PD 098059 on AChR c subunit expression would likely 
be a result of specific inhibition of MEK. Sol 8 cells trans- 
fected  with  enlacZ  or  t-CAT  were  pretreated  with  PD 
098059 for 30 rain before treatment with ARIA. 24 h later, 
cultures were either fixed and subjected to 13-galactosidase 
histochemistry or harvested for CAT assays. MEK inhibi- 
tor did  not affect basal enlacZ or t-CAT expression but 
specifically  abolished  the  ARIA-induced  increase  in 
AChR  c  subunit  expression  (Fig.  3,  A  and  B).  As  ex- 
pected, Sol 8 myotubes pretreated with MEK inhibitor 30 
rain  before  stimulation  with  ARIA  displayed  levels  of 
erkl and erk2 phosphorylation indistinguishable from that 
in unstimulated cells (Fig. 4 B). 
To further test the involvement of MAPKs, we evalu- 
ated  the  temporal characteristics of MAPK activation in 
response to ARIA stimulation by using an antibody spe- 
cific for activated (phosphorylated) forms of the MAPKs 
erkl  (p44)  and  erk2  (p42).  Stimulation  with  ARIA  re- 
sulted  in  significant  increases  in  the  activated  forms  of 
erkl and erk2 (Fig. 4 A). Similarly, we observed a 2-4-fold 
increase in endogenous erkl and erk2 activity within min- 
utes of ARIA stimulation which remained elevated for at 
least 1 h, when MAPK activity was measured with an im- 
mune complex assay (data not shown). Thus, the rapid and 
prolonged  activation  of erkl  and  erk2 in  ARIA-treated 
Sol 8 cells and the inhibitory action of PD 098059 on both 
ARIA-induced MAPK activation and AChR c subunit ex- 
pression,  are  consistent  with  the  necessary  role  of  the 
MAPK pathway in transduction of the ARIA signal. 
Requirement  for PI3K in ARIA-induced AChR E 
Subunit Gene Expression 
Activation of an erbB2/erbB3 receptor complex by ARIA 
may recruit not only the Ras pathway but also the PI3K 
pathway  (see  Introduction).  We  asked  whether  there  is 
detectable activation of PI3K in our system, and if such ac- 
tivation is necessary and sufficient for eliciting the ARIA- 
induced increase in AChR c subunit gene expression. Us- 
ing  a  phosphorylation  assay which  detects  PI  to  PI(3)P 
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the  MEK  inhibitor PD  098059.  (A)  Western  blot  analysis of 
ARIA-induced MAPK activation in Sol 8 cells. 15 I~g of Sol 8 myo- 
tube protein in SDS Laemmli sample buffer were subject to elec- 
trophoresis on  10%  polyacrylamide gels, blotted, and  probed 
with  antibodies specific for  tyrosine/threonine phosphorylated 
MAPKs, erkl and erk2 (NEB). MAPK activity, as indicated by 
phosphorylation, increased within  minutes  of stimulation with 
ARIA, and remained elevated for as long as 1 h. Data shown rep- 
resent data obtained from three independent experiments. (B) 
In-gel MAPK assay. Extracts (25 ~g protein) prepared from Sol 8 
cells treated with MEK inhibitor (PD 098059, 50 I~M) and ARIA 
(3 nM HRG), as indicated, were used as a source of MAPK (erk) 
activity in an in-gel kinase assay with myelin basic protein (MBP) 
and  [~/-32p]ATP as  substrates.  Radioactivity was  visualized by 
phosphorimager  analysis.  ARIA-dependent activation  of erkl 
and erk2 was inhibited by PD 098059. Data shown represent data 
obtained from three to four independent experiments. See text 
for description of inhibitor. 
Figure 3.  Inhibition of ARIA-induced expression of GnlacZ and 
G-CAT by the MEK inhibitor PD 098059. (A) GnlacZ or (B) G-CAT 
constructs were transiently transfected into Sol 8 myotubes. At 24 h 
after the induction of differentiation, a DMSO vehicle (a and a') 
or the MEK inhibitor PD 098059, 50 IxM (b and b ') was added to 
the wells 30 min before addition of ARIA (3 nM HRG) (a' and b '). 
One day later, cultures were either fixed or harvested for analy- 
sis. Each condition was performed in duplicate. The data shown 
in A  are representative of results obtained in three to four inde- 
pendent transfections; Bar, 300 p~m. In B, the data shown repre- 
sent average values from four to five independent transfections. 
Error bars indicate SEM. See text for description of plasmids and 
inhibitor. 
conversion,  we  measured  PI3K  activity in  extracts  from 
ARIA-treated and untreated  Sol 8  myotubes. Cells were 
stimulated with  ARIA  for specified periods of time  and 
harvested in PI3K lysis buffer. Since activated PI3K asso- 
ciates with  tyrosine-phosphorylated proteins,  cell lysates 
were  immunoprecipitated  by using  anti-phosphotyrosine 
antibody (4G10)  to  enrich lysates with  PI3K protein be- 
fore PI3K assays (Newberry and Pike, 1995). We observed 
a  rapid and transient 10-12-fold increase in PI3K activity 
in  extracts  of ARIA-treated Sol 8  myotubes  (Fig. 5  A). 
Thus,  an  activated  (tyrosine  phosphorylated)  ARIA  re- 
ceptor may recruit PI3K to mediate the ARIA signal. 
To  determine  if ARIA-induced specific association of 
PI3K with erbB kinases, lysates from ARIA-treated Sol 8 
cells were immunoprecipitated with an anti-erbB2 or anti- 
erbB3 antibody and processed for either PI3K activity as- 
say or immunoblot analysis. In unstimulated Sol 8 cells, no 
significant  association  of  PI3K  activity  with  erbB2  or 
erbB3  was  detected.  However,  after  ARIA  stimulation, 
erbB3-associated  PI3K  activity  increased  dramatically 
(Fig. 5  B).  In  contrast,  association of PI3K  activity with 
erbB2  was  not  observed in  extracts  from  ARIA-treated 
cells immunoprecipitated with anti-erbB2 antibody. West- 
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ErbB3  in Sol 8 myotubes.  (A) ARIA-dependent PI3K activity 
analyzed by thin layer chromatography. Cells were treated  with 
ARIA (3 nM HRG) for the times indicated in minutes, lysed, im- 
munoprecipitated  with anti-phosphotyrosine  antibody,  and  as- 
sayed for PI3K activity. The origin (ori) of the chromatogram and 
the position of PI 3-phosphate  (PIP) are indicated. M, radiola- 
beled PIP marker. Sample variations at the origin can be ascribed 
to carry-over of highly radioactive aqueous  (nonlipid) material 
during organic extractions (Auger et al., 1990). (B) ARIA-depen- 
dent association of PI3K activity with erbB3. Cells were treated 
with ARIA (3 nM HRG) for 3 min, lysed, immunoprecipitated 
with antibodies to erbB2 and erbB3, and assayed for PI3K activ- 
ity. Lysates incubated with normal rabbit serum (NRS) were used 
as  controls  for nonspecific associations of PI3K  in  stimulated 
cells,  ori,  origin; PIP,  PI  3-phosphate;  M,  radiolabeled  PIP 
marker.  (C)  Western  blot  analysis was  performed  to confirm 
quantitative immunoprecipitation  of erbB2 with anti-erbB2 anti- 
body from unstimulated and ARIA-treated Sol 8 cells. Aliquots 
of immune complexes obtained as described for PI3K activity as- 
says were solubilized in Laemmli SDS sample buffer and 30 Izg 
protein subjected to 10% PAGE, blotted, and probed with anti- 
bodies specific for erbB2 or erbB3 (not shown). Immunoprecipi- 
tation  of erbB2 from extracts of HRG-treated mammary carci- 
noma cells (MDA-MB-453) was used as a positive control, lane 
labeled as C. 
ern  blot analysis was performed to confirm quantitative 
immunoprecipitation of erbB2 (Fig. 5 C).  We found that 
comparable  levels  of  erbB2  were  immunoprecipitated 
from extracts of Sol 8 cells and a breast carcinoma cell line 
overexpressing erbB2 (Culouscou et al.,  1993).  Thus, we 
conclude that  ARIA stimulation  leads  to  rapid  recruit- 
ment of PI3K to the activated erbB3 receptor. 
Given the ARIA-dependent activation of PI3K, we de- 
termined  whether the  activation of PI3K is  sufficient to 
substitute  for the ARIA-elicited increase in AChR e ex- 
pression.  Cells were eotransfected with either enlacZ or 
e-CAT reporter constructs and a constitutively active PI3K 
(AcPI3K) (see Materials and Methods). Expression of the 
activated PI3K, but not a kinase-deficient PI3K construct 
(AAcPI3K), increased  expression  of enlacZ  (Fig.  6  A). 
Similarly, expression of AcPI3K but not AAcPI3K, increased 
expression of e-CAT (Fig.  6 B). Thus, an activated PI3K 
turns on a pathway that mimics ARIA-receptor activation 
and thus, elicits  increases in AChR e subunit gene expres- 
sion. 
Since our results  suggested that  activation of a  PI3K- 
dependent pathway was sufficient to substitute for ARIA 
receptor activation, we investigated whether PI3K activa- 
tion was necessary as well as sufficient for AChR gene ex- 
pression. LY294002, a potent and stable synthetic inhibi- 
tor of PI3K, has been shown to inhibit activation of PI3K 
in human neutrophils and smooth muscle cells. Moreover, 
it does not inhibit a number of ATP-requiring enzymes, in- 
cluding PI4K, EGF receptor tyrosine kinase, c-src, MAPKs, 
$6 kinase, diacylglycerol kinase, protein kinase C, cAMP- 
dependent  protein  kinase,  and  ATPase  (Vlahos  et  al., 
1994). To establish the selectivity of LY294002 for PI3K in 
Sol 8 cells, we confirmed that the compound did not inhibit 
ARIA-induced activation of MAPKs. Stimulation  with ARIA 
(5  min)  in cells pretreated for 30 min with LY294002 or 
DMSO did not inhibit the ARIA-dependent activation of 
both erkl and erk2 MAPKs as measured by in-gel kinase 
assay (data not shown), indicating that LY294002 does not 
inhibit MAPK activity in our cell culture system. There- 
fore, any effects of LY294002 on ARIA-induction of e gene 
expression could be reasonably attributed to specific inhi- 
bition of PI3K activity. Sol 8 cells were transfected with ei- 
ther enlacZ or e-CAT. Before stimulation with ARIA, cells 
were pretreated for 30 min with LY294002 or the DMSO 
vehicle and were assayed for lacZ or CAT 24--48 h later. 
LY294002 did not affect basal expression of ¢nlacZ; how- 
ever, it completely abolished the ARIA-induced increase 
in  AChR e  subunit  expression  as  indicated  by minimal 
13-galactosidase  nuclear staining (Fig. 6 A). Thus, selective 
inhibition of PI3K prevents transduction of the ARIA sig- 
nal and blocks activation of enlacZ.  Comparable results 
were obtained with LY294002 in e-CAT-transfected cells 
(data  not shown).  Thus,  we have demonstrated that  (a) 
ARIA stimulation  results  in  rapid  association  of  PI3K 
with the erbB3 receptor, (b) that the presence of a consti- 
tutively active  PI3K is  sufficient  to mimic the  action of 
ARIA on AChR e subunit gene expression, and (c) that 
selective inhibition of PI3K blocks the ARIA induction of 
AChR e subunit gene expression. Together, these results 
suggest that activation of a PI3K-dependent pathway is a 
prerequisite  for eliciting a  complete ARIA-mediated in- 
crease in AChR e subunit gene expression. 
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Figure 6.  Induction of AChR e expression in Sol 8 cells by activated 
PI3K and inhibition of ARIA-induced expression by the PI3K inhibitor 
LY294002.  (A)  GnlacZ was cotransfected with  (a and  a ~  activated 
PI3K  (AcPI3K);  (b  and  b')  kinase-deficient  activated  PI3K 
(AAePI3K); (c and c ~) pSKII+ as DNA filler plus 30 min incubation 
with LY294002 in DMSO vehicle to inhibit endogenous PI3K activity 
before addition of ARIA (3 nM HRG) (a '-c'). Cultures were fixed for 
13-galactosidase analysis  2 d later or 1 d later (d and d'). Each condi- 
tion was performed in duplicate.  The data shown are representative of 
results obtained in three to four independent transfections. Bar, 300 
ixm. (B) G-CAT was cotransfected with pSKII+ DNA filler, AcPI3K, 
or AAcPI3K into Sol 8 cells. At 24 h after the induction of differentia- 
tion, ARIA (3 nM HRG) was added to the wells.  Cells  were har- 
vested for analysis 2 d later. Each plasmid set was transfected in dupli- 
cate;  the  data  shown  represent  average  values  from  four  to  five 
independent  transfections.  ActinCAT was used to demonstrate  the 
specificity  of ARIA induction of G-CAT expression and showed no 
sensitivity  to signaling  constructs. Error bars indicate SEM. See text 
for description of plasmids. 
Relationship between RaslMAPK and PI3K in 
ARIA Signaling 
Since  our  results  suggest  that  ARIA  signaling  requires 
both a Ras-dependent and a PI3K-dependent component, 
we investigated how the two pathways interact to induce 
AChR  e  subunit  expression.  We  performed  a  series  of 
cotransfection experiments  to establish  the epistatic rela- 
tionship between the two in this system. 
First, we tested the possibility that Ras/Raf/MAPK were 
downstream effectors of PI3K. We asked whether inhibi- 
tion of the Ras/MAP kinase  cascade could interfere  with 
the ability of AcPI3K to activate the AChR e subunit re- 
porter construct. The ARIA-independent increase in ~-CAT 
expression  stimulated  by the  AcPI3K construct  alone  is 
abolished when the cells are also expressing  a  dominant- 
negative Ras, and is significantly attenuated when the cells 
are expressing AcPI3K plus a dominant-negative Raf (Fig. 
7 A). We next investigated if pharmacological inhibition of 
the MAPK pathway downstream of Ras could also block 
the inductive effect of AcPI3K on AChR e subunit expres- 
sion. Cells transfected with e-CAT plus the activated PI3K 
(AcPI3K)  were  treated  with  the  MEK  inhibitor  PD 
098059 before stimulation with ARIA. We found that the 
ARIA-independent increase in e-CAT expression induced 
by AcPI3K was completely abolished by the MEK inhibi- 
tor.  Thus,  e-CAT  expression  in  cells  transfected  with 
AcPI3K and treated  with  PD 098059 is indistinguishable 
from basal e-CAT expression in unstimulated cells (Fig. 7 A). 
Thus, the MEK inhibitor blocked both the expression of 
AChR ~ subunit by ARIA (Fig. 3) and by AcPI3K. These 
results may imply that AcPI3K mimics ARIA by activat- 
ing  a  Ras/Raf/MAPK-mediated  pathway  essential  for 
ARIA-induced AChR ~ subunit  expression  and  without 
these downstream effectors, activation of PI3K in this sys- 
tem is insufficient for full induction of the AChR e subunit 
construct.  Alternatively,  these  results  may suggest that if 
the Ras- and PI3K-dependent components are distinct, the 
PI3K-activated component alone is not sufficient for full 
expression of the AChR ~ subunit gene. 
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ARIA-dependent induction of e-CAT expression in Sol 8 tran- 
sient transfection. Cells were cotransfected with e-CAT and sig- 
naling  constructs  as  indicated  and  subject  to inhibition  of the 
MAPK pathway (with PD 098059)  or inhibition  of PI3K (with 
LY294002)  before addition of 3 nM HRG where indicated. Cells 
were harvested for CAT analysis  as described elsewhere.  Each 
plasmid set was transfected in duplicate; the data shown repre- 
sent average values from four independent transfections. Error 
bars indicate SEM. See text for description of plasmids and inhib- 
itors. 
Finally, we considered  the possibility that  the Ras  and 
PI3K-dependent  components  may  be  distinct  and  may 
have to be active simultaneously for AChR e  subunit  in- 
duction. Thus, we asked whether induction of AChR e sub- 
unit  expression  by AcRaf also displayed  dependence  on 
activation  of endogenous  PI3K.  Sol  8  cells  were  trans- 
fected with  e-CAT plus AcRaf and subsequently  treated 
with  LY294002 to inhibit  endogenous  PI3K activity.  We 
found that the PI3K inhibitor blocks all expression of e-CAT, 
both ARIA-induced and AcRaf-induced (Fig. 7 B). As ex- 
pected, LY294002 also blocked AcRas-induced e-CAT ex- 
pression  (data not shown). More importantly, high levels 
of MAPK  activity in  Sol  8  cells  transfected  with  AcRaf 
and  treated  with  LY294002  confirmed  adequate  expres- 
sion  of AcRaf and  selectivity  of the  inhibitor  for  PI3K 
(data  not shown).  Therefore,  the  PI3K inhibitor  blocked 
induction of AChR e subunit by ARIA (Fig. 3 A) and by 
AcRaf.  Thus,  PI3K  activity  appears  to  be  necessary  for 
complete  induction of AChR e  subunit  expression  by an 
activated Ras/MAPK cascade. 
Discussion 
We  have  investigated  the  signaling  pathways  by  which 
ARIA  exerts  its  inductive  effects  on gene  expression  at 
the neuromuscular junction.  In the studies reported here, 
we have  demonstrated  (a)  ARIA-independent  induction 
of AChR e subunit gene expression by direct activation of 
either PI3K or the Ras/MAPK pathway, (b) inhibition of 
ARIA-induced  AChR  e  subunit  expression  by  interfer- 
ence  with  the  MAPK  cascade  or  PI3K  activity,  and  (c) 
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Figure 8.  Schematic model  of signaling  pathways required  for 
ARIA-regulated synapse-specific AChR e gene expression at the 
neuromuscular junction.  The nerve terminal  provides the  neu- 
rotrophic factor ARIA at the nerve end-plate.  Probable recep- 
tors  for  ARIA  include  erbB2  and  erbB3.  ARIA-dependent 
dimerization and activation of these receptors leads to the associ- 
ation of various SH2 domain-containing signaling molecules (i.e., 
PI3K, Ras, etc.) with the tyrosine-phosphorylated RTKs. Trans- 
duction of the ARIA transynaptic signals to increase AChR e sub- 
unit expression requires the interaction of a Ras/MAPK-depen- 
dent component and a PI3K-dependent component. Activation 
of either pathway is sufficient to mimic ARIA-induced gene 
expression.  Inhibition of either pathway by dominant-negative 
constructs  (DnRas,  DnRaf)  or pharmacological inhibitors  (PD 
098059 and LY294002) is sufficient to block ARIA-induced AChR e 
expression via the other. Transduction of the transynaptic signals 
to the nucleus may lead to activation of regulatory molecules in- 
volved  in  transcription  of  AChR  and  other  synapse-specific 
genes.  Dashed  arrows  represent  potential  routes  suggested by 
our data. See Discussion for detailed description of the model. 
ARIA-dependent association of PI3K activity with erbB3 
receptor. 
Based on these results and previous studies, we propose 
a  model for ARIA-induced synapse-specific gene expres- 
sion (Fig. 8).  ARIA is released  by the motor-neuron in a 
spatially restricted manner into the synaptic cleft where it 
binds to and activates an erbB2/erbB3 heterodimeric com- 
plex at the motor-endplate  (Altiok et al.,  1995; Moscoso 
et  al.,  1995;  Zhu  et  al.,  1995).  ARIA  1/2induced  cross- 
phosphorylation of erbB3 by erbB2 might be expected to 
result  in  tyrosine  phosphorylation  of  specific  residues, 
some of which may represent docking sites for the p85 reg- 
ulatory subunit  of PI3K (YXXM)  or for the Ras adapter 
Grb2  (YXNR)  (Carraway  and  Cantley,  1994).  Recruit- 
ment  of PI3K and  Ras  by the  activated  ARIA-receptor 
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ways  (Fig.  8): shown  in  our studies  to be  necessary for 
AChR ~ subunit expression. The target transactivating fac- 
tors responsible for direct induction of AChR ~ subunit 
expression in subsynaptic nuclei are unknown at present. 
However, in light of recent reports of Ets-binding proteins 
as targets of Ras-mediated signaling in C.  elegans,  Dro- 
sophila, and other mammalian systems, these highly con- 
served transcription factors are likely to play an important 
role (Wasylyk et al., 1993; Conrad et al., 1994). 
Cross-talk between various signaling pathways involving 
protein phosphorylation is an emerging theme in intracel- 
lular communication (for review see Bourne, 1995; Hunter, 
1995). Our findings indicate that transduction of the ARIA 
neurotrophic signal for induction of AChR ~ subunit gene 
expression at the neuromuscular synapse requires the con- 
comitant activation of PI3K and a Ras-mediated pathway. 
Specifically, inhibition of either pathway with either domi- 
nant-negative constructs or pharmacological inhibitors was 
sufficient to block expression of AChR ~ subunit by ARIA. 
Moreover, even when one pathway was artificially turned 
on with activated constructs, inhibition of the second path- 
way with either dominant-negative constructs or pharma- 
cological inhibitors  blocked the  ability  of the  activated 
pathway to induce expression of AChR ~ subunit reporter 
construct. Since the specificity of the drugs is critical to the 
proposal that both pathways are necessary for induction of 
AChR ~ subunit expression, it is important to note that al- 
though the PI3K inhibitor (LY294002) blocked AcRaf in- 
duction  of  AChR  gene  expression,  it  did  not  inhibit 
ARIA-induced MAPK activation in Sol 8 cells. Likewise, 
although the MEK inhibitor (PD 098059) blocked AcPI3K 
induction of AChR gene expression, we confirmed that it 
did not do so by inhibiting endogenous PI3K activation. 
Thus, although it may be argued that the lack of induction 
of AChR ¢ subunit was the result of either drug blocking 
the activity of some other protein(s), it seems unlikely that 
another protein equally sensitive to both LY294002 and 
PD 098059 is involved in induction of AChR subunit gene 
expression. Therefore, a more likely explanation for these 
results is that each pathway depends on the other for com- 
plete  activation,  since  both  are  necessary  and  neither 
alone is sufficient for induction of AChR ~ subunit gene. 
In addition, results with activated constructs and epistatic 
experiments suggested that there is cross-talk between the Ras 
and PI3K pathways. It was recently reported that the p85 
regulatory subunit of PI3K can bind directly to the Ras 
adapter Grb2 (Wang et al., 1995). Therefore, activation of 
one pathway may result in subsequent  activation of the 
other, generating the necessary downstream signals for full 
induction of AChR  ¢ subunit  expression in  subsynaptic 
nuclei. 
Alternatively, ARIA may activate separate Ras-depen- 
dent and PI3K-dependent signaling components, neither 
of which is able to generate all the necessary downstream 
signals to increase AChR ~ subunit expression when the 
other is inhibited. Thus, a basal level of activity from each 
ARIA-induced  signaling  pathway may be required in  a 
permissive manner for full activation of gene expression 
by  the  other  ARIA-induced  pathway.  PI3K  may  work 
partly through Ras in this and other systems but may also 
provide a  Ras-independent signal which alone is insuffi- 
cient to mediate the ARIA signal for induction of AChR 
subunit gene. It should be noted that some PI3K-mediated 
actions have been shown to be Ras-dependent while oth- 
ers have not. In PC12 cells, NGF induces differentiation 
and  survival  via  recruitment  of  PI3K  but  not  Ras  or 
MAPKs  (Yao  and  Cooper, 1995).  In contrast, PI3K re- 
quires Ras for c-los transcription in fibroblasts and oocyte 
maturation in Xenopus (Hu et al., 1995) as well as for me- 
diating the PDGF receptor mitogenic signal  (Valius and 
Kazlauskas, 1993). In our system, the apparent Ras-depen- 
dent component of PI3K activity may account for some, 
but not all, of its actions in activation of AChR ~ subunit 
expression. 
Future studies may focus on defining how the synaptic 
pathways activated by ARIA are coordinately regulated 
with pathways elicited by electrical activity known to re- 
press  AChR  gene  expression.  Both a  cAMP-dependent 
(Chahine et al., 1993) and a protein kinase C--dependent 
pathway (Klarsfeld et al., 1989; Huang et al., 1994) have 
been implicated in mediating this repression. PKC may an- 
tagonize the action of ARIA by inhibiting the formation 
of  activated  ARIA  receptor  complexes  (Altiok  et  al., 
1995) or by inactivating transcription factors in the myo- 
genic  pathway  necessary  for  AChR  gene  expression 
(Laufer and Changeux, 1989; Li et al.,  1992). These and 
other alternatives remain to be explored. 
In summary, regulation of synapse-specific gene expres- 
sion by ARIA via the PI3K and the Ras/MAPK pathway 
further expands the  range of developmentally regulated 
cellular processes  shown  to  be  critically determined  by 
these signaling pathways. Moreover, it raises the possibil- 
ity that similar signaling mechanisms may be involved in 
the development and differentiation of central synapses. 
Future  investigations of signal  transduction  mechanisms 
involved in the development and maintenance of the neu- 
romuscular junction may be aided by the molecular tools 
designed for these studies. 
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